Atlas Trials

Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma

Clinical trial NCT05565807 · RECRUITING

Trial details

NCT number
NCT05565807
Sponsor
Zhejiang ACEA Pharmaceutical Co. Ltd.
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Relapsed or Refractory Multiple Myeloma
Start date
2023-02-09
Primary completion
2026-12-31
Enrollment
84

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.